Skip to content
Medical Health Aged Care

Monash Expert: World Diabetes Day – Tuesday 14 November

Monash University 3 mins read

Tomorrow (Tuesday 14 November) is World Diabetes Day.

This year’s theme is know your risk for type 2 diabetes to help delay or prevent the condition and the importance of having access to the right information and care to ensure timely treatment and management.

Available to comment:

Associate Professor Anthony Dear, Eastern Health Clinical School, Monash University
Contact details: +61 (0) 410 400 010, or anthony.dear@monash.edu 
Read diabetes-related stories on Monash Lens here

  • Type 2 diabetes
  • Trialling new diabetes treatments
  • Weight and diabetes

The following can be attributed to Associate Professor Dear:

“It’s never too late to make a conscious effort to reduce the health problems associated with type 2 diabetes. Diet, regular exercise, healthy eating and weight, together with medications if required, can avert the long-term health consequences of type 2 diabetes, which include cardiovascular disease impacting heart, brain, kidneys, eyes and legs. We do have choices and modern medicine can potentially help make these choices a little easier.

“The following risk factors are the most significant contributors to the development of type 2 diabetes:

  • Prediabetes, where the blood sugar levels are higher than normal but less than those used in the diagnosis of type 2 diabetes
  • Being overweight
  • Over 55 years old
  • 45 years or older and overweight
  • Over 35 years and Aboriginal or Torres Strait Islander background, or Pacific Island, Indian or Chinese background
  • Family history of type 2 diabetes e.g. parent, brother, or sister with it
  • Smoking
  • Physically active less than three times a week
  • Have had gestational diabetes (diabetes during pregnancy)

“Prevention is much better than cure! The following can assist in the prevention of type 2 diabetes:

Lose weight and keep it off. You may be able to prevent or delay diabetes by losing five to seven per cent of your starting weight.

Move more. Get at least 30 minutes of physical activity five days a week. If you have not been active, talk with your health care professional about which activities are best. Start slowly to build up to your goal.

Eat healthy foods most of the time. Eat smaller portions to reduce the amount of calories you eat each day and help you lose weight. Choosing foods with less fat is another way to reduce calories. Drink water instead of sweetened beverages.

Stop smoking. Smokers are 30-40 per cent more likely to develop type 2 diabetes.

Drug therapies aimed at lowering blood glucose and weight loss in patients with prediabetes.

“Research into the incretin hormone system is where the big news is coming from when we talk about new treatments for type 2 diabetes.

  • The body makes a hormone called Glucagon Like Peptide-1 (GLP-1) which is released from the gut when we eat. GLP-1 binds to GLP-1 receptors (GLP-1R) in the pancreas to increase insulin secretion and lower blood glucose.
  • This finding has led to the development of an injectable class of drugs called the GLP-1R agonists which lower blood glucose.
  • Interestingly the GLP-R agonist drugs also seem to have the added benefit of significant weight loss and improvement in cardiovascular disease outcomes in patients with type 2 diabetes … a win-win for these patients!
  • Longer acting GLP-1R agonists (e.g. Ozempic and Wegovy) are now being used to treat not only type 2 diabetes but also obesity in the hope of preventing onset and progression of type 2 diabetes.
  • Recently, new drugs which target multiple components of the incretin hormone system have been developed e.g. Tirzepatide (TGA approved for type 2 diabetes) which may be superior in effect to current GLP-1R agonists. Orally active GLP-1R agonists are also being trialled (e.g. Orforglipron) averting the need to inject on a daily or weekly basis as is currently required when using GLP-1R agonists.”

For more Monash media stories visit our news & events site: monash.edu/news
For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or media@monash.edu

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.